

Supplementary data

Site-specific methylation and acetylation of lysine residues in the C-terminal domain (CTD) of RNA polymerase II

Kirsten Voss¹, Ignasi Forné², Nicolas Descostes³, Corinna Hintermair¹, , Roland Schüller¹, Muhammad Ahmad Maqbool⁶, Martin Heidemann¹, Andrew Flatley⁴, Axel Imhof³, Marta Gut⁵, Ivo Gut⁵, Elisabeth Kremmer⁴, Jean-Christophe Andrau⁶ and Dirk Eick^{1,7}

¹Department of Molecular Epigenetics, Helmholtz Center Munich, Center for Integrated Protein Science Munich, Marchioninstr. 25, 81377 Munich, Germany.


²Biomedical Center Munich, Ludwig Maximilians University Munich, Großhaderner Strasse 9, 82152 Planegg-Martinsried, Germany.

³Centre d'Immunologie de Marseille-Luminy, Université Aix-Marseille, Campus de Luminy, France.

⁴Institute of Molecular Immunology, Helmholtz Center Munich, Marchioninstr. 25, 81377 Munich, Germany.

⁵Centre Nacional D'Anàlisi Genòmica, Parc Científic de Barcelona, Barcelona, Spain.

⁶Institute of Molecular Genetics of Montpellier (IGMM), UMR5535 CNRS, 34293, Montpellier, France.



Amino acid composition of human RNAPII CTD and purification of RNAPII.

(A) Human CTD is composed of 52 consensus and non-consensus heptad repeats. Peptides of CTD after tryptic digestion are marked by red and blue boxes, basic amino acids by red letters.

(B) Purification scheme of RNAPII large subunit Rpb1.


Figure S1

YSPTSpPKacYSPTSPK

Peptide Summary									
Fragment Matches									
Value Type: Theo. Mass [Da]									
Ion Series	Phosphorylation Losses	Neutral Losses	Multiple Neutral Losses	Precursor Ions					
#1	b ⁺	b ²⁺	b ³⁺	Seq.	y ⁺	y ²⁺	y ³⁺	#2	
1	164.07060	82.53894	55.36172	Y				14	
2	251.10263	126.05495	84.37239	S	1498.68256	749.84492	500.23237	13	
3	348.15540	174.58134	116.72332	P	1411.65053	706.32890	471.22169	12	
4	449.20308	225.10518	150.40588	T	1314.59776	657.80252	438.87077	11	
5	616.20144	308.60436	206.07200	S-Phospho	1213.55008	607.27868	405.18821	10	
6	713.25421	357.13074	238.42292	P	1046.55172	523.77950	349.52209	9	
7	883.35974	442.18351	295.12477	K-Acetyl	949.49895	475.25311	317.17117	8	
8	1046.42306	523.71517	349.47921	Y	779.39341	390.20034	260.46932	7	
9	1133.45509	567.23118	378.48988	S	616.33009	308.66868	206.11488	6	
10	1230.50786	615.75757	410.84081	P	529.29806	265.15267	177.10420	5	
11	1331.55554	666.28141	444.52337	T	432.24529	216.62628	144.75328	4	
12	1418.58757	709.79742	473.53404	S	331.19761	166.10244	111.07072	3	
13	1515.64034	758.32381	505.88497	P	244.16558	122.58643	82.06004	2	
14				K	147.11281	74.06004	49.70912	1	

Fragment Spectrum


Extracted from: E:\Discoverer\IgnasiRSchuller_Final_Sample_Set_Feb_2013\WTrec\WT_2_Yst_Pol_IJA.RAW #2735 RT: 67.56
 ITMS, CID@35.00, z=+3, Mono m/z=554.59113 Da, MH+=1661.75882 Da, Match Tol.=0.6 Da



MS/MS spectrum of peptide with heptad-repeats 39-40

Figure S2


YSPTSpPKacYSPTSPKme₁



MS/MS spectrum of peptide with heptad-repeats 39-40

Figure S3


YSPT_pSPKme₁YSPTSpPTYS_pPTTPK



MS/MS spectrum of peptide with heptad-repeats 40-42


Figure S4

YSPT_pSPTYSP_TTPKme₁



MS/MS spectrum of peptide with heptad-repeats 41-42

Figure S5




(A) Reactivity of mAb 1F5 for RNAPII in cellular extracts of human cell lines HeLa, U2OS, H1299, and Raji, and mouse cell line NIH3T3.

(B) Titration of the specificity of mAb 1F5 for K7me1 and K7me2 epitopes in ELISA using synthetic di-heptad peptides with the corresponding modification.



Figure S6

Peptide	Sequence	Modification
1	TSPSYSPTSPKYSPTSPS-PEG-Biotin	-
2	TSPSYSPTSP K_{me2} YSPTSPS-PEG-Biotin	Kme2
3	TSPSYSPT S_p PKYSPTSPS-PEG-Biotin	Ser5P
4	TSPSYSPT S_p P K_{me2} YSPTSPS-PEG-Biotin	Ser5P, Kme2
5	TSPSYSPTSPKY S_p PTSPS-PEG-Biotin	Ser2P
6	TSPSYSPTSP K_{me2} Y S_p PTSPS-PEG-Biotin	Kme2, Ser2P
7	TSPSYSPT S_p PKY S_p PTSPS-PEG-Biotin	Ser2P/Ser5P
8	TSPSYSPT S_p P K_{me2} Y S_p PTSPS-PEG-Biotin	Ser2P/Ser5P, Kme2



Phosphorylation of adjacent amino acids (red) can inhibit reactivity of mAb 1F5. ELISA experiment.

Figure S7

A**B**

Recognition of RNAPII by mAb 1F5 requires CTD K7 residues.
 (A) recWT: wild-type CTD; recWT-K/S: K7 containing heptads were replaced by consensus repeats; Con48, CTD with 48 consensus repeats.
 (B) Western analysis of RNAPII mutants with mAb 1F5.

Figure S8